Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

2.

Resveratrol and Its Effects on the Vascular System.

Breuss JM, Atanasov AG, Uhrin P.

Int J Mol Sci. 2019 Mar 27;20(7). pii: E1523. doi: 10.3390/ijms20071523. Review.

3.

Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases.

Michalak B, Piwowarski JP, Granica S, Waltenberger B, Atanasov AG, Khan SY, Breuss JM, Uhrin P, Żyżyńska-Granica B, Stojakowska A, Stuppner H, Kiss AK.

J Nat Prod. 2019 Feb 22;82(2):375-385. doi: 10.1021/acs.jnatprod.8b00939. Epub 2019 Jan 17.

PMID:
30653318
4.

Vascular Morphogenesis in the Context of Inflammation: Self-Organization in a Fibrin-Based 3D Culture System.

Rüger BM, Buchacher T, Giurea A, Kubista B, Fischer MB, Breuss JM.

Front Physiol. 2018 Jun 5;9:679. doi: 10.3389/fphys.2018.00679. eCollection 2018.

5.

Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways.

Wang D, Uhrin P, Mocan A, Waltenberger B, Breuss JM, Tewari D, Mihaly-Bison J, Huminiecki Ł, Starzyński RR, Tzvetkov NT, Horbańczuk J, Atanasov AG.

Biotechnol Adv. 2018 Nov 1;36(6):1586-1607. doi: 10.1016/j.biotechadv.2018.04.006. Epub 2018 Apr 21. Review.

PMID:
29684502
6.

Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation.

Uhrin P, Wang D, Mocan A, Waltenberger B, Breuss JM, Tewari D, Mihaly-Bison J, Huminiecki Ł, Starzyński RR, Tzvetkov NT, Horbańczuk J, Atanasov AG.

Biotechnol Adv. 2018 Nov 1;36(6):1608-1621. doi: 10.1016/j.biotechadv.2018.04.002. Epub 2018 Apr 17. Review.

PMID:
29678389
7.

Constituents of Mediterranean Spices Counteracting Vascular Smooth Muscle Cell Proliferation: Identification and Characterization of Rosmarinic Acid Methyl Ester as a Novel Inhibitor.

Liu R, Heiss EH, Waltenberger B, Blažević T, Schachner D, Jiang B, Krystof V, Liu W, Schwaiger S, Peña-Rodríguez LM, Breuss JM, Stuppner H, Dirsch VM, Atanasov AG.

Mol Nutr Food Res. 2018 Apr;62(7):e1700860. doi: 10.1002/mnfr.201700860. Epub 2018 Mar 30.

PMID:
29405576
8.

Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.

Liu R, Heiss EH, Schachner D, Jiang B, Liu W, Breuss JM, Dirsch VM, Atanasov AG.

J Nat Prod. 2017 Jul 28;80(7):2146-2150. doi: 10.1021/acs.jnatprod.7b00268. Epub 2017 Jun 19.

9.

Premature senescence of endothelial cells upon chronic exposure to TNFα can be prevented by N-acetyl cysteine and plumericin.

Khan SY, Awad EM, Oszwald A, Mayr M, Yin X, Waltenberger B, Stuppner H, Lipovac M, Uhrin P, Breuss JM.

Sci Rep. 2017 Jan 3;7:39501. doi: 10.1038/srep39501.

10.

Protective role of the matricellular protein CCN3 in abdominal aortic aneurysm.

Uhrin P, Breuss JM.

J Thorac Dis. 2016 Sep;8(9):2365-2368. No abstract available.

11.

The brain-tumor related protein podoplanin regulates synaptic plasticity and hippocampus-dependent learning and memory.

Cicvaric A, Yang J, Krieger S, Khan D, Kim EJ, Dominguez-Rodriguez M, Cabatic M, Molz B, Acevedo Aguilar JP, Milicevic R, Smani T, Breuss JM, Kerjaschki D, Pollak DD, Uhrin P, Monje FJ.

Ann Med. 2016 Dec;48(8):652-668. Epub 2016 Aug 25.

12.

Drugs from nature targeting inflammation (DNTI): a successful Austrian interdisciplinary network project.

Waltenberger B, Atanasov AG, Heiss EH, Bernhard D, Rollinger JM, Breuss JM, Schuster D, Bauer R, Kopp B, Franz C, Bochkov V, Mihovilovic MD, Dirsch VM, Stuppner H.

Monatsh Chem. 2016;147:479-491. Epub 2016 Feb 25. Review.

13.

Plumericin inhibits proliferation of vascular smooth muscle cells by blocking STAT3 signaling via S-glutathionylation.

Heiss EH, Liu R, Waltenberger B, Khan S, Schachner D, Kollmann P, Zimmermann K, Cabaravdic M, Uhrin P, Stuppner H, Breuss JM, Atanasov AG, Dirsch VM.

Sci Rep. 2016 Feb 9;6:20771. doi: 10.1038/srep20771.

14.

Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases.

Blažević T, Heiss EH, Atanasov AG, Breuss JM, Dirsch VM, Uhrin P.

Evid Based Complement Alternat Med. 2015;2015:654098. doi: 10.1155/2015/654098. Epub 2015 Sep 17. Review.

15.

Discovery and resupply of pharmacologically active plant-derived natural products: A review.

Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H.

Biotechnol Adv. 2015 Dec;33(8):1582-1614. doi: 10.1016/j.biotechadv.2015.08.001. Epub 2015 Aug 15. Review.

16.

In vivo Tube Assay: An Optimised Protocol of the Directed in vivo Angiogenesis Assay by Implementing Immunohistochemistry.

Unseld M, Breuss JM, Pausz C, Pablik E, Schabbauer G, Zielinski CC, Uhrin P, Prager GW.

J Vasc Res. 2015;52(2):116-26. doi: 10.1159/000434751. Epub 2015 Jul 31.

PMID:
26277802
17.

PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis.

Unseld M, Chilla A, Pausz C, Mawas R, Breuss J, Zielinski C, Schabbauer G, Prager GW.

Thromb Haemost. 2015 Aug;114(2):379-89. doi: 10.1160/TH15-01-0016. Epub 2015 Apr 30.

PMID:
25925849
18.

Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo.

Fakhrudin N, Waltenberger B, Cabaravdic M, Atanasov AG, Malainer C, Schachner D, Heiss EH, Liu R, Noha SM, Grzywacz AM, Mihaly-Bison J, Awad EM, Schuster D, Breuss JM, Rollinger JM, Bochkov V, Stuppner H, Dirsch VM.

Br J Pharmacol. 2014 Apr;171(7):1676-86. doi: 10.1111/bph.12558.

19.

Imbricaric acid and perlatolic acid: multi-targeting anti-inflammatory depsides from Cetrelia monachorum.

Oettl SK, Gerstmeier J, Khan SY, Wiechmann K, Bauer J, Atanasov AG, Malainer C, Awad EM, Uhrin P, Heiss EH, Waltenberger B, Remias D, Breuss JM, Boustie J, Dirsch VM, Stuppner H, Werz O, Rollinger JM.

PLoS One. 2013 Oct 9;8(10):e76929. doi: 10.1371/journal.pone.0076929. eCollection 2013.

20.

Underlying pathways for interferon risk to type II diabetes mellitus.

Abdel-Hamid N, Jubori TA, Farhan A, Mahrous M, Gouri A, Awad E, Breuss J.

Curr Diabetes Rev. 2013 Nov;9(6):472-7. Review.

PMID:
24111619
21.

Cold induces reactive oxygen species production and activation of the NF-kappa B response in endothelial cells and inflammation in vivo.

Awad EM, Khan SY, Sokolikova B, Brunner PM, Olcaydu D, Wojta J, Breuss JM, Uhrin P.

J Thromb Haemost. 2013 Sep;11(9):1716-26. doi: 10.1111/jth.12357.

22.

uPAR: a modulator of VEGF-induced angiogenesis.

Uhrin P, Breuss JM.

Cell Adh Migr. 2013 Jan-Feb;7(1):23-6. doi: 10.4161/cam.22124. Epub 2012 Oct 17.

23.

VEGF-initiated angiogenesis and the uPA/uPAR system.

Breuss JM, Uhrin P.

Cell Adh Migr. 2012 Nov-Dec;6(6):535-615. doi: 10.4161/cam.22243. Epub 2012 Oct 17. Review.

24.

The interferon stimulated gene 12 inactivates vasculoprotective functions of NR4A nuclear receptors.

Papac-Milicevic N, Breuss JM, Zaujec J, Ryban L, Plyushch T, Wagner GA, Fenzl S, Dremsek P, Cabaravdic M, Steiner M, Glass CK, Binder CJ, Uhrin P, Binder BR.

Circ Res. 2012 Apr 13;110(8):e50-63. doi: 10.1161/CIRCRESAHA.111.258814. Epub 2012 Mar 15.

PMID:
22427340
25.

VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution.

Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, Schütz GJ, Freissmuth M, Breuss JM.

Cardiovasc Res. 2012 Apr 1;94(1):125-35. doi: 10.1093/cvr/cvs017. Epub 2012 Jan 26.

27.

Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease.

Rein P, Vonbank A, Saely CH, Beer S, Jankovic V, Boehnel C, Breuss J, Risch L, Fraunberger P, Drexel H.

Am J Cardiol. 2011 Apr 15;107(8):1144-8. doi: 10.1016/j.amjcard.2010.12.011. Epub 2011 Feb 15.

PMID:
21324429
28.

Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease.

Vonbank A, Saely CH, Rein P, Beer S, Breuss J, Boehnel C, Drexel H.

Clin Chim Acta. 2011 May 12;412(11-12):1003-7. doi: 10.1016/j.cca.2011.02.008. Epub 2011 Feb 12.

PMID:
21320476
29.

Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation.

Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, Soler-Cardona A, Ondrovicová G, Kutejová E, Steinhuber E, Breuss J, Drach J, Petzelbauer P, Binder BR, Stockinger H.

Circ Res. 2011 Mar 18;108(6):676-85. doi: 10.1161/CIRCRESAHA.110.234732. Epub 2011 Jan 27.

PMID:
21273553
30.

Proteomic characterization of human early pro-angiogenic cells.

Urbich C, De Souza AI, Rossig L, Yin X, Xing Q, Prokopi M, Drozdov I, Steiner M, Breuss J, Xu Q, Dimmeler S, Mayr M.

J Mol Cell Cardiol. 2011 Feb;50(2):333-6. doi: 10.1016/j.yjmcc.2010.11.022. Epub 2010 Dec 13.

PMID:
21147123
31.

Indirubin-3'-monoxime blocks vascular smooth muscle cell proliferation by inhibition of signal transducer and activator of transcription 3 signaling and reduces neointima formation in vivo.

Schwaiberger AV, Heiss EH, Cabaravdic M, Oberan T, Zaujec J, Schachner D, Uhrin P, Atanasov AG, Breuss JM, Binder BR, Dirsch VM.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2475-81. doi: 10.1161/ATVBAHA.110.212654. Epub 2010 Sep 16.

PMID:
20847306
32.

Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation.

Uhrin P, Zaujec J, Breuss JM, Olcaydu D, Chrenek P, Stockinger H, Fuertbauer E, Moser M, Haiko P, Fässler R, Alitalo K, Binder BR, Kerjaschki D.

Blood. 2010 May 13;115(19):3997-4005. doi: 10.1182/blood-2009-04-216069. Epub 2010 Jan 28.

PMID:
20110424
33.

The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo.

Rychli K, Kaun C, Hohensinner PJ, Rega G, Pfaffenberger S, Vyskocil E, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Niessner A, Maurer G, Huber K, Wojta J.

J Thromb Haemost. 2010 Mar;8(3):596-604. doi: 10.1111/j.1538-7836.2010.03741.x. Epub 2009 Dec 17.

34.

Low bone mineral density is not associated with angiographically determined coronary atherosclerosis in men.

Beer S, Saely CH, Hoefle G, Rein P, Vonbank A, Breuss J, Gaensbacher B, Muendlein A, Drexel H.

Osteoporos Int. 2010 Oct;21(10):1695-701. doi: 10.1007/s00198-009-1103-y. Epub 2009 Nov 21.

PMID:
19936870
35.

Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures.

Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, Boulanger CM, Westwood N, Urbich C, Willeit J, Steiner M, Breuss J, Xu Q, Kiechl S, Mayr M.

Blood. 2009 Jul 16;114(3):723-32. doi: 10.1182/blood-2009-02-205930. Epub 2009 Apr 15.

PMID:
19369228
36.

Vascular morphogenesis by adult bone marrow progenitor cells in three-dimensional fibrin matrices.

Rüger BM, Breuss J, Hollemann D, Yanagida G, Fischer MB, Mosberger I, Chott A, Lang I, Davis PF, Höcker P, Dettke M.

Differentiation. 2008 Sep;76(7):772-83. doi: 10.1111/j.1432-0436.2007.00259.x. Epub 2008 Jan 3.

PMID:
18177424
37.

Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo.

Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K, Wojta J.

Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1587-95. Epub 2007 May 24.

PMID:
17525365
38.

Regulation of protein C inhibitor (PCI) activity by specific oxidized and negatively charged phospholipids.

Malleier JM, Oskolkova O, Bochkov V, Jerabek I, Sokolikova B, Perkmann T, Breuss J, Binder BR, Geiger M.

Blood. 2007 Jun 1;109(11):4769-76. Epub 2007 Mar 1.

PMID:
17332248
39.

Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions.

Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Erne P, Binder BR, Leitinger N.

Circ Res. 2006 Oct 13;99(8):900-8. Epub 2006 Sep 14.

PMID:
16973904
40.

Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth.

Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J, Wagner O, Bischoff M, Clauss M, Binder BR, Hofer E.

Cancer Res. 2006 Jul 1;66(13):6708-13.

41.

Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor.

Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM, Stockinger H, Binder BR.

Circ Res. 2004 Jun 25;94(12):1562-70. Epub 2004 May 6.

PMID:
15131009
42.

Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity.

Kopp CW, Hölzenbein T, Steiner S, Marculescu R, Bergmeister H, Seidinger D, Mosberger I, Kaun C, Cejna M, Horvat R, Wojta J, Maurer G, Binder BR, Breuss JM, Ecker RC, de Martin R, Minar E.

Blood. 2004 Mar 1;103(5):1653-61. Epub 2003 Oct 30.

PMID:
14592830
43.

Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells.

Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR.

Blood. 2004 Feb 1;103(3):955-62. Epub 2003 Oct 2.

PMID:
14525763
44.

Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression.

Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I, de Martin R, Binder BR.

Blood. 2003 Apr 15;101(8):3042-8. Epub 2002 Dec 27.

PMID:
12506026
45.

Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes.

Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, Losert UM, Maurer G, Pacher R, Huber K, Wojta J.

J Mol Cell Cardiol. 2002 Dec;34(12):1681-91.

PMID:
12505065
46.

The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration.

Leksa V, Godár S, Cebecauer M, Hilgert I, Breuss J, Weidle UH, Horejsí V, Binder BR, Stockinger H.

J Biol Chem. 2002 Oct 25;277(43):40575-82. Epub 2002 Aug 19.

47.

Inhibition of neointimal formation after stent placement with adenovirus-mediated gene transfer of I kappa B alpha in the hypercholesterolemic rabbit model: initial results.

Cejna M, Breuss JM, Bergmeister H, de Martin R, Xu Z, Grgurin M, Losert U, Plenk H Jr, Binder BR, Lammer J.

Radiology. 2002 Jun;223(3):702-8.

PMID:
12034938
48.

Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model.

Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR.

Circulation. 2002 Feb 5;105(5):633-8.

PMID:
11827931
49.
50.

Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue.

Korschineck I, Ziegler S, Breuss J, Lang I, Lorenz M, Kaun C, Ambros PF, Binder BR.

J Biol Chem. 2001 Apr 20;276(16):13192-7. Epub 2001 Jan 10.

Supplemental Content

Loading ...
Support Center